Zhao, Shijia
Wu, Wei
Samant, Saurabhi
Khan, Behram
Kassab, Ghassan S.
Watanabe, Yusuke
Murasato, Yoshinobu
Sharzehee, Mohammadali
Makadia, Janaki
Zolty, Daniel
Panagopoulos, Anastasios
Burzotta, Francesco
Migliavacca, Francesco
Johnson, Thomas W.
Lefevre, Thierry
Lassen, Jens Flensted
Brilakis, Emmanouil S.
Bhatt, Deepak L.
Dangas, George
Chiastra, Claudio
Stankovic, Goran
Louvard, Yves
Chatzizisis, Yiannis S.
Funding for this research was provided by:
National Institutes of Health (R01 HL144690-01)
Dr Vincent Miscia Cardiovascular Research Fund
Article History
Received: 10 December 2020
Accepted: 16 July 2021
First Online: 13 August 2021
Competing interests
: Yiannis S. Chatzizisis: Speaker honoraria, advisory board fees and research grant from Boston Scientific Inc.; Advisory board fees and research grant from Medtronic Inc.; Issued U.S. patent (No. 11,026,749) and international patent pending (application No. PCT/US2020/057304) for the invention entitled “Computational simulation platform for the planning of interventional procedures”; Co-founder of ComKardia Inc. Emmanouil S. Brilakis: Consulting/Speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), CSI, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; Research support from Regeneron and Siemens: Shareholder in MHI Ventures. Francesco Burzotta: Speaker honoraria from Medtronic, Abbott and Abiomed. Deepak L. Bhatt: Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda. Thomas Johnson: Speaker/consultancy fees from Abbott Vascular, Boston Scientific, Medtronic, Terumo, and Vascular Perspectives. Research grants from AstraZeneca and Bayer. Thierry Lefèvre: Speaker/consultancy fees from Abbott Vascular, Boston Scientific, and Terumo. All other authors have no relevant conflict of interests to disclose.